immunitybio.com (IBRX) Value Adjusted for Debt and Cash

NantKwest (IBRX) - corporate logo

The complexity of developing oncology drugs and the colossal costs of testing create a high barrier to entry in the industry. The current Enterprise Value of ImmunityBio, Inc. (IBRX) stands at 9149.22, and this daily price action, visualized for analytical convenience, allows for an assessment against the backdrop of scaling challenges and dependence on the founder's funds. ImmunityBio, Inc. (IBRX) relies on a unique NK-cell system, developing Anktiva to combat bladder tumors.

IBRX (ImmunityBio, Inc.) Total Company Value history from 11/23/2025 to 10/27/2026

ImmunityBio, Inc. - analytical breakdowns and key metrics (IBRX)

- price and consensus price forecast:
Price Chart ImmunityBio Inc|IBRX - Price Target Chart
- market capitalization data:
Market Value ImmunityBio|IBRX - Real Price to Acquire Entire Company
- book capitalization data:
Equity per Share ImmunityBio|IBRX - Company Book Value|Market-to-Book Ratio immunitybio.com|IBRX - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio ImmunityBio, Inc.|IBRX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio immunitybio.com|IBRX - Company Debts|Debts to Book Value ImmunityBio
Fundamental valuation:ImmunityBio Inc (IBRX)
Original product of ImmunityBio

Enterprise Value (EV) combines market capitalization and net debt, reflecting the actual cost of a full asset buyout adjusted for liquidity. By analyzing historical EV levels, an investor can filter out speculative noise to assess whether the current valuation of ImmunityBio, Inc. (IBRX) is justified given the high capital burn rate and critical dependence on regulatory verdicts for new drugs.

Competitors of ImmunityBio, Inc. (IBRX)

Immunocore Holdings - Total Company Value|Total Company Value Janux Pharma (JANX)|Arcus Corp (RCUS) - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company Zymeworks Inc.|TNGX (tangotx.com) - Business Value|Total Company Value IOVA (Iovance Biotherapeutics, Inc.)|Total Enterprise Value IMTX|Total Company Value Xencor Corp XNCR|Business Value Compass Therapeutics Corp (CMPX)|Replimune Group, Inc. - Enterprise Value|lyell.com - Real Price to Acquire Entire Company|IPHA (Innate Pharma) - Total Company Value|PYXS: Total Enterprise Value|cgen.com (CGEN) - Total Company Value|IOBT (IO Biotech Inc.) - Total Company Value|Total Company Value STRO (Sutro Biopharma, Inc.)|Total Enterprise Value minktherapeutics.com|HOWL: Enterprise Value|Full Takeover Company Value immixbio.com IMMX|ALXO: Real Price to Acquire Entire Company|CUE - Total Enterprise Value|Real Price to Acquire Entire Company PDS Biotechnology Corp (PDSB)|SONN - Value Adjusted for Debt and Cash|MAIA Biotechnology, Inc. - Enterprise Value|LIMN (Liminatus Pharma Inc.) - Company Buyout Price|Total Company Value LVTX|Real Price to Acquire Entire Company NXTC|Total Company Value LPTX (Leap Therapeutics, Inc.)|Real Price to Acquire Entire Company intensitytherapeutics.com INTS|Real Price to Acquire Entire Company SNSE (Sensei Biotherapeutics, Inc.)|Theriva Biologics Inc - Enterprise Value|Gritstone Bio (GRTS) - Total Company Value|KA: Business Value|Total Company Value NEXI|Total Enterprise Value Turnstone Biologics Corp.|Vaccinex - Real Price to Acquire Entire Company|Full Takeover Company Value Harpoon Therapeutics Inc (HARP)